Advances in Melanoma: From Pathogenesis to Personalized Therapy

Dear Colleagues,

This Special Issue will focus on the latest clinical advancements in melanoma management, emphasizing personalized treatment strategies and real-world applications. Contributions will highlight the evolving role of targeted therapies (BRAF/MEK inhibitors) and immunotherapy (PD-1/CTLA-4 blockade) in improving survival outcomes in advanced melanoma. Key discussions in this area include predictive biomarkers for treatment selection, strategies to overcome therapy resistance, and the integration of novel combination therapies into clinical practice. This Special Issue will also explore emerging diagnostic tools, such as liquid biopsies and imaging advancements, for early detection and monitoring. Additionally, real-world data on treatment sequencing, adjuvant therapy optimization, and long-term survivorship will be addressed. By bridging translational research and clinical practice, this Special Issue will provide actionable insights for oncologists to utilize in enhancing melanoma care. To encompass the entire journey of melanoma care, the latest developments in palliative care, including spiritual care, will be discussed.

Dr. Patricia Tai
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.